Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

Abstract Background Interleukin-5 (IL-5) antibodies represent a promising therapeutic option for patients with severe eosinophilic asthma. To date, no official treatment response criteria exist. In this study, simple criteria for treatment response applicable to all asthma patients were used to eval...

Full description

Bibliographic Details
Main Authors: Nora Drick, Benjamin Seeliger, Tobias Welte, Jan Fuge, Hendrik Suhling
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Pulmonary Medicine
Subjects:
Severe eosinophilic asthma
Mepolizumab
Treatment response
IL-5
Lung function
Online Access:http://link.springer.com/article/10.1186/s12890-018-0689-2

Internet

http://link.springer.com/article/10.1186/s12890-018-0689-2

Similar Items